NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free ENLV Stock Alerts $1.45 -0.05 (-3.33%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.44▼$1.4950-Day Range$1.27▼$4.3152-Week Range$1.15▼$4.59Volume52,572 shsAverage Volume161,377 shsMarket Capitalization$26.93 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enlivex Therapeutics alerts: Email Address Enlivex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside382.8% Upside$7.00 Price TargetShort InterestHealthy1.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.86) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsMedical Sector368th out of 907 stocksPharmaceutical Preparations Industry161st out of 422 stocks 3.5 Analyst's Opinion Consensus RatingEnlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.50% of the outstanding shares of Enlivex Therapeutics have been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently increased by 17.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENLV. Previous Next 1.9 News and Social Media Coverage News SentimentEnlivex Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enlivex Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ENLV on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.02% of the stock of Enlivex Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Enlivex Therapeutics Stock (NASDAQ:ENLV)Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Read More ENLV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENLV Stock News HeadlinesApril 24, 2024 | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Given "Buy" Rating at HC WainwrightApril 22, 2024 | finance.yahoo.comEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 18, 2024 | msn.comYet Another Biotech Stock Has Found Success During Tuesday's SessionApril 17, 2024 | msn.comEnlivex Therapeutics (ENLV) Price Target Decreased by 41.67% to 7.14April 16, 2024 | finance.yahoo.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 16, 2024 | globenewswire.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 15, 2024 | americanbankingnews.comEnlivex Therapeutics Ltd. Expected to Post FY2025 Earnings of ($0.55) Per Share (NASDAQ:ENLV)April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 13, 2024 | stockhouse.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With SepsisApril 11, 2024 | finance.yahoo.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | globenewswire.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | msn.comNasdaq Gains Over 50 Points; US Producer Prices Increase In MarchApril 11, 2024 | msn.comEnlivex stock plunges 50% on mixed results from sepsis studyApril 11, 2024 | msn.comDow Dips 100 Points; CarMax Earnings Miss ViewsApril 11, 2024 | globenewswire.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisApril 5, 2024 | msn.comENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023March 22, 2024 | finanznachrichten.deEnlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 16, 2024 | finance.yahoo.comENLV Apr 2024 7.500 callMarch 9, 2024 | edition.cnn.comEnlivex Therapeutics Ltd.February 26, 2024 | finance.yahoo.comEnlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee OsteoarthritisFebruary 22, 2024 | benzinga.comEnlivex Therapeutics Stock (NASDAQ:ENLV), Short Interest ReportFebruary 22, 2024 | finance.yahoo.comENLV May 2024 5.000 putFebruary 7, 2024 | finance.yahoo.comEnlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing MethodJanuary 17, 2024 | finance.yahoo.comEnlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisDecember 20, 2023 | finance.yahoo.comEnlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With SepsisDecember 16, 2023 | morningstar.comEnlivex Therapeutics Ltd ENLVSee More Headlines Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/25/2024Next Earnings (Estimated)6/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENLV CUSIPN/A CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+373.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-71.00% Return on Assets-59.08% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio7.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.91Miscellaneous Outstanding Shares18,570,000Free Float16,286,000Market Cap$27.43 million OptionableOptionable Beta1.02 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Shai Novik M.B.A. (Age 58)Executive Chairman Comp: $528kDr. Oren Hershkovitz Ph.D. (Age 47)Chief Executive Officer Comp: $273.6kProf. Dror Mevorach M.D. (Age 68)Founder and Chief Scientific & Medical Officer Comp: $180kMs. Shachar Shlosberger CPA (Age 47)Chief Financial Officer Comp: $126kMr. Veronique Amor-BaroukhSenior Director of OperationsMs. Sigal AradDirector of HRMore ExecutivesKey CompetitorsSensei BiotherapeuticsNASDAQ:SNSEUnity BiotechnologyNASDAQ:UBXVaxxinityNASDAQ:VAXXCytoMed TherapeuticsNASDAQ:GDTCOncternal TherapeuticsNASDAQ:ONCTView All Competitors ENLV Stock Analysis - Frequently Asked Questions Should I buy or sell Enlivex Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENLV shares. View ENLV analyst ratings or view top-rated stocks. What is Enlivex Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued twelve-month price targets for Enlivex Therapeutics' shares. Their ENLV share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 382.8% from the stock's current price. View analysts price targets for ENLV or view top-rated stocks among Wall Street analysts. How have ENLV shares performed in 2024? Enlivex Therapeutics' stock was trading at $2.70 on January 1st, 2024. Since then, ENLV shares have decreased by 46.3% and is now trading at $1.45. View the best growth stocks for 2024 here. Are investors shorting Enlivex Therapeutics? Enlivex Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 278,700 shares, an increase of 17.9% from the March 31st total of 236,400 shares. Based on an average trading volume of 169,300 shares, the short-interest ratio is presently 1.6 days. View Enlivex Therapeutics' Short Interest. When is Enlivex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024. View our ENLV earnings forecast. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) released its quarterly earnings results on Friday, March, 29th. The company reported ($0.48) earnings per share (EPS) for the quarter. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENLV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
